WaveMan
WaveMan · Company
VANI · Vivani Medical, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

VANI Vivani Medical (VANI) Insider Trading, Ownership & Congress Trades

Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0001266806
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
13
13F, latest reported quarter

What the filings say about VANI

Insiders, 180 days
+$5.0M net bought
1 buyer

Vivani Medical insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Vivani Medical, Inc. insiders bought a net $5.0M of stock across 135 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Williams Gregg
Director
BUY
2026-07-16 SECtraded 2026-07-15
793,650
$1.0M
-13.6%
Context
  • 95 earlier Form 4 trades (code P or S) here by this insider (95 buys), the last on Jun 15, 2026.
  • +23.1% median (+22.4% mean) 90-day return after 30 previous buys.
  • The trade is 2.2% of the 36,912,736 shares held after it.
  • No other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Williams Gregg bought about $1,000.0K of VANI on Jul 15, 2026; 13 funds added in the latest 13F quarter.
Williams Gregg
Director
BUY
2026-06-16 SECtraded 2026-06-15
1,587,301
$2.0M
-0.9%
Context
  • 94 earlier Form 4 trades (code P or S) here by this insider (94 buys), the last on May 15, 2026.
  • +23.9% median (+24.6% mean) 90-day return after 30 previous buys.
  • The trade is 4.4% of the 36,119,086 shares held after it.
  • No other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Williams Gregg bought about $2.0M of VANI on Jun 15, 2026; 13 funds added in the latest 13F quarter.
Williams Gregg
Director
BUY
2026-05-19 SECtraded 2026-05-15
1,587,301
$2.0M
-4.2%
Context
  • 93 earlier Form 4 trades (code P or S) here by this insider (93 buys), the last on Apr 15, 2026.
  • +24.5% median (+26.1% mean) 90-day return after 30 previous buys.
  • The trade is 4.6% of the 34,531,785 shares held after it.
  • No other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Williams Gregg bought about $2.0M of VANI on May 15, 2026; 13 funds added in the latest 13F quarter.
Williams Gregg
Director
BUY
2026-04-16 SECtraded 2026-04-15
1,587,301
$2.0M
-14.9%
Context
  • 92 earlier Form 4 trades (code P or S) here by this insider (92 buys), the last on Mar 15, 2026.
  • +24.5% median (+27.5% mean) 90-day return after 30 previous buys.
  • The trade is 4.8% of the 32,944,484 shares held after it.
  • No other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Williams Gregg bought about $2.0M of VANI on Apr 15, 2026; 13 funds added in the latest 13F quarter.
Williams Gregg
Director
BUY
2026-03-16 SECtraded 2026-03-15
264,551
$333.3K
-5.8%
Context
  • 90 earlier Form 4 trades (code P or S) here by this insider (90 buys), the last on Feb 15, 2026.
  • +24.6% median (+29.9% mean) 90-day return after 30 previous buys.
  • The trade is 0.8% of the 31,357,183 shares held after it.
  • No other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Williams Gregg bought about $333.3K of VANI on Mar 15, 2026; 13 funds added in the latest 13F quarter.
135 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 130 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$5.0M over 180 days
+$5.0M of it by a 10%+ holder
more than 96% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
13 funds bought in last quarter
below 80% of Medical Devices
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
1.3% of the float short (float per yahoo 2026-10-26) · 2.6 days to cover · settled 2026-09-30
below 78% of Medical Devices
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 3 in the prior 90
Why it matters
The absence is the signal: 3 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch VANI

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-30.1%12M
-42%-25%-8%+9%2025-102025-122026-022026-042026-062026-082026-10 2025-10-27 · Williams Gregg bought $6.0M2026-01-27 · Williams Gregg bought $2.0M2026-04-15 · Williams Gregg bought $2.0M2026-05-15 · Williams Gregg bought $2.0M2026-06-15 · Williams Gregg bought $2.0M2025-11-15 · Williams Gregg bought $1.6M2025-12-15 · Williams Gregg bought $1.6M2026-01-15 · Williams Gregg bought $1.6M2026-02-15 · Williams Gregg bought $1.6M2026-03-15 · Williams Gregg bought $1.4M2026-07-15 · Williams Gregg bought $1,000.0K2025-12-15 · Williams Gregg bought $333.3K2026-01-15 · Williams Gregg bought $333.3K2026-02-15 · Williams Gregg bought $333.3K2026-03-15 · Williams Gregg bought $333.3K2025-11-15 · Williams Gregg bought $333.3K2025-12-29 · Mendelsohn Aaron bought $24.6K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns VANI: institutional holders (13F)

13F holdings, latest reported quarter
VANGUARD CAPITAL MANAGEMENT LLC
1,768,077 sh
$2.2M
Tanager Wealth Management LLP
607,276 sh
$753.0K
GEODE CAPITAL MANAGEMENT, LLC
587,745 sh
$728.9K
TUDOR INVESTMENT CORP ET AL
410,902 sh
$509.5K
COMMONWEALTH EQUITY SERVICES, LLC
330,565 sh
$409.9K

Congress trades in VANI

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

VANI planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

VANI mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$165.8K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$10.4K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$374.6K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$798.3K position · as of 2026-06-30
0.0%
Victory Extended Market Index Fund
$5.9K position · as of 2026-07-31
0.0%
Fidelity Nasdaq Composite Index Fund
$62.9K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Adam Mendelsohn
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$1.1M
$915.2K
$770.4K
+37%
n/a
2023
$1.0M
$954.8K
$693.5K
+20%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $5.0M bought by insiders over 180 days, 13 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

VANI financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2024-07-01 to 2025-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$26.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.12x
current debt only, 2021-03-31 (63 months older than the period end); equity 2026-06-30
Cash flow to debt
-11.50x
TTM operating cash flow over current debt only, 2021-03-31 (63 months older than the period end)
Return on equity
+225.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+76.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-95.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$85.1M
market value at close 2026-10-27 on 2026-08-13 shares, plus current debt only, 2021-03-31 (63 months older than the period end), minus cash 2026-06-30
FCF yield
-25.8%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$0$0n/an/a
Operating income-$27.6M-$24.7M-$27.0M-$21.2M
Net income$26.6M$23.5M$25.7M-$13.9M
EPS (diluted)-0.43-0.43-0.50n/a
Operating cash flow-$24.3M-$20.8M-$23.7M-$18.8M
Cash$16.2M$18.4M$20.7M$45.1M
SEC XBRL, fiscal years, as known on 2026-10-28

VANI Stock Sonar score 5/7 axes

Find similar shapesCompare

VANI ranks highest on insider conviction (74th percentile) and profitability (73rd), and lowest on institutional and government (20th), among Medical Devices peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
73
Inputs
  • Return on equity+225.4% · 99 pct, sector of 183
  • Return on assets+76.3% · 99 pct, sector of 214
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-95.2% · 20 pct, sector of 188
Financial health
39
Inputs
  • Debt to equity0.12x · 66 pct, sector of 159
  • Cash flow to debt-11.50x · 11 pct, sector of 150
Insider conviction
74
Inputs
  • Net Form 4 buying (codes P and S), 180d$5.0M · 96 pct, sector of 140
  • Insider buyers, 180d1 · 52 pct, sector of 142
Institutional and government
20
Inputs
  • Funds adding, latest quarter13 · 20 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
60
Inputs
  • Short interest, % of float+1.3% · 77 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+11.9% · 43 pct, sector of 198
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

VANI filings, in plain words

Are Vivani Medical insiders buying or selling VANI?

In the 180 days to 2026-10-28, Vivani Medical insiders were net buyers, a net $5.0M across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, Vivani Medical insiders were net buyers of VANI, a net $5.0M across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $5.0M, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies